|
Forward Looking
Statements This communication contains forward-looking statements that are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Terminology such as may, will, should,
expects, intends, plans, anticipates, believes, estimates,
predicts, j i l i d h i il i l h i f h i d d id if hf dl ki 2
projects, potential, continue, and other similar terminology or the
negative of these terms, are intended to identify such forward-looking
statements, but their absence does not mean that a particular statement is
not forward-looking. Such forward-looking statements are not guarantees of
future performance and are subject to risks and uncertainties that may cause
actual results to differ materially from those anticipated by the
forward-looking statements. These statements are not guarantees of future
performance, involve risks, uncertainties and assumptions that are difficult
to predict, and are based upon assumptions as to future events that may not
prove accurate. Examples of such forward looking statements include Allos and
AMAGs expectations with respect to the synergies, costs and other
anticipated financial impacts of the proposed transaction; future financial
and operating results of the combined company, including potential future revenues,
milestone payments and royalties; the combined company's plans, objectives,
expectations and intentions with respect to future clinical development and
marketing programs; expectations and intentions with respect to future
operations; approval of the proposed transaction by requisite stockholders;
the satisfaction of the closing conditions to the proposed transaction; and
the timing of the completion of the proposed transaction. In any
forwardlooking statement in which AMAG or Allos expresses an expectation or
belief as to future results, such expectation or belief is expressed in good
faith and believed to have a reasonable basis, but there can be no assurance
that the statement or expectation or belief will result or be achieved or
accomplished. The following factors, among others, could cause actual results
to differ materially from those described in the forwardlooking statements:
failure of Allos or AMAG stockholders to approve the proposed transaction;
the challenges and costs of closing the proposed transaction, integrating the
two companies, restructuring the combined company; the possibility that the
expected synergies will not be realized, or will not be realized within the
expected time period; the possibility that future clinical development and
marketing programs may be delayed or revised; the ability to retain key
employees; and other economic, business, competitive, and/or regulatory
factors affecting the businesses of Allos and AMAG generally, including those
set forth in the filings of Allos and AMAG with the Securities and Exchange
Commission, especially in the g y, g g g , p y Risk Factors section of
Allos Quarterly Report on Form 10-Q for the quarter ended March 31, 2011
filed with the SEC on May 10, 2011, the Risk Factors section of AMAGs
Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 filed with
the SEC on May 9, 2011, and in Allos and AMAGs other periodic reports and
filings with the SEC. Allos and AMAG cautions investors not to place undue
reliance on the forward-looking statements contained herein. All
forward-looking statements are based on information currently available to
Allos and AMAG on the date hereof, and Allos and AMAG undertake no obligation
to revise or update these forward-looking statements to reflect events or
presentation required by law circumstances after the date of this
presentation, except as law.
|